NanoVibronix Expands Board of Directors with Appointment of Two New Independent Directors
January 13 2022 - 8:30AM
Business Wire
Strengthens Board with Strategic, Corporate
Governance and Financial Expertise
NanoVibronix Inc., (NASDAQ: NAOV), a medical
device company that produces the UroShield® and PainShield® Surface
Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today
announced its board of directors has appointed Ms. Aurora (Rori)
Cassirer and Ms. Maria (Lulu) Schroeder to serve as independent
directors effective today.
Ms. Cassirer will serve on the compensation and nominating and
governance Committees and Ms. Schroeder will serve on the audit
Committee. Following the appointments, the board of NanoVibronix
will be comprised of eight directors, six of whom are considered
‘independent’ as defined under the Nasdaq Listing Rules.
Brian Murphy, Chief Executive Officer of NanoVibronix Inc.,
commented, “We are adding two highly-talented and successful
professionals that broaden the skill set of our board and will
enhance our ability to execute on our strategic objective of
growing our business. We expect Rori and Lulu will be instrumental
in advancing strategic initiatives and providing thought leadership
in a variety of legal, financial and managerial roles. We have no
doubt this experience will be enormously beneficial as we further
commercialize our products and expand our manufacturing
capabilities to penetrate the healthcare market.”
Aurora (Rori) Cassirer
Ms. Cassirer is a highly experienced attorney, who has served as
a partner in prominent law firms for more than 30 years including
Troutman Pepper, where she served on the Executive and Compensation
Committees, and Jenkins & Gilchrist. In addition to her
management responsibilities, Rori has a sophisticated practice
focusing on business litigation and corporate governance issues.
She has developed a particular niche in dealing with publicly and
privately held biotech/healthtech and biopharma companies. Ms.
Cassirer has been listed as AV Preeminent by Martindale-Hubbell
consistently for the last 20 years as well as being listed in Law
& Politics’ New York Super Lawyers for excellence in Business
Litigation every year since 2008. Previously, she served as Chair
of the Advisory Board of ReferWell, f/k/a Urgent Consult, LLC, a
start-up in the health tech business. She also serves on the Board
of Directors of Kids in Need of Defense (KIND), a not-for-profit
organization where she served on its Compensation Committee. She is
also a member of the Board of Friends of Jerusalem College of
Technology and serves on its Development Committee. She serves as
co-chair of the New York State Bar Association International
Corporate Compliance Committee and on the Advisory Board of
LiveCare Corp., a company engaged in the manufacturing and
distribution of remote monitoring devices of patients. Ms. Cassirer
received her JD from New York University.
Maria (Lulu) Schroeder
Ms. Schroeder has been a key Financial Executive at a number of
public and privately-held companies including CST Brands, KCI and
Brain Sentinel, where she recently served as Chief Financial
Officer. Prior to Brain Sentinel, Ms. Schroeder served as Vice
President, Global Tax of CST Brands, a Fortune 250 retail Oil and
Gas company. Prior to that, she served as Vice President and
Treasurer & Head of Tax at Kinetic Concepts, Inc. (“KCI”) a
$1.5 billion MedTech company, which was recently purchased by 3M
for $6.7 billion. At KCI, she held key roles in a number of
strategic transactions, including two leveraged buyouts and an
initial public offering. Ms. Schroeder began her career at Ernst
& Whinney before joining Deloitte Haskins & Sells. Ms.
Schroeder is an alumnus of San Antonio Leadership, a premier
leadership program of the San Antonio Chamber of Commerce and has
served on the Audit Committee for The University of Texas at San
Antonio, as Treasurer of Girls, Inc. of San Antonio and as a board
member of KLRN, San Antonio’s public television station. Ms.
Schroeder is a Certified Public Accountant and Chartered Global
Management Accountant with a B.B.A. in Accounting from the
University of Texas at San Antonio.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®
and UroShield®, which are portable devices suitable for
administration at home without assistance of medical professionals.
Additional information about NanoVibronix is available at:
www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as foreign currency exchange rate fluctuations,
logistical and communications challenges, the burden and cost of
compliance with foreign laws, and political and/or economic
instabilities in specific jurisdictions; and (xv) market and other
conditions. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220113005120/en/
Investor Contacts: Brett Maas, Managing Principal, Hayden
IR, LLC brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024